Hutchison China MediTech Ltd.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment covers all activities related to oncology/immunology including sales, marketing, manufacturing and research and development with respect to drugs and drug candidates. The Other Ventures segment includes all other HUTCHMED businesses. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

— FRUZAQLA is the first targeted therapy approved in the U.S. for metastatic colorectal cancer regardless of biomarker status or prior types of therapies in more than a decade —

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data from several ongoing studies of fruquintinib, in combination with chemotherapies and/or immunotherapies, will be presented at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2023, taking place on October 20-24, 2023 in Madrid, Spain.

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

The mean of analysts' price targets for HUTCHMED (HCM) points to a 107.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 107.24% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?

— Third major market authorization application based on data from the FRESCO-2 global Phase III trial — — Third major market authorization application based on data from the FRESCO-2 global Phase III trial —

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

iRobot

Twilio

Though artificial intelligence and machine learning have gotten their fair share of hype this year, not all of these companies are positioned to outperform in 2023. This has led to the rise of machine learning stocks to avoid.

Beware! 3 Machine Learning Stocks Waving Massive Red Flags Right Now

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today announces that results from the confirmatory Phase IIIb clinical trial of savolitinib in patients with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration non-small cell lung cancer (“NSCLC”), were presented during the  IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (“WCLC”), which took place from September 9 to 12, 2023 in Singapore.

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed patient enrollment of a bridging study of tazemetostat in China.

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China's National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to savolitinib for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction (“GEJ”) adenocarcinoma patients with mesenchymal epithelial transition factor (“MET”) amplification who have failed at least two lines of standard therapies.

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints —

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

Hutchmed (China) Limited, a Chinese biopharma company, has experienced fluctuations in its stock price but has potential for improvement. The company acts as a liaison between the healthcare systems of China and the U.S., working to get its products approved in both countries. Hutchmed (China) Limited has a vast pipeline of products, with several in clinical trials, and has major collaborations with companies like Takeda and AstraZeneca.

Hutchmed: Attractive Chinese R&D Giant

HUTCHMED (China) Limited (NASDAQ:HCM ) Q2 2023 Earnings Conference Call July 31, 2023 8:00 AM ET Company Participants Mark Lee - SVP, Corporate Finance & Development Wei-Guo Su - CEO, Chief Scientific Officer & Executive Director Johnny Cheng - CFO & Executive Director Chen Hong - SVP & Chief Commercial Officer, China Mike Shi - EVP, Head, R&D and Chief Medical Officer Karen Atkin - EVP & COO Conference Call Participants Alec Stranahan - Bank of America Merrill Lynch Paul Choi - Goldman Sachs Group Mike Mitchell - Panmure Gordon Matthew Yan - CLSA Operator Good day, and thank you for standing by. Welcome to HUTCHMED 2023 Half Year Financial Results Presentation.

HUTCHMED (China) Limited (HCM) Q2 2023 Earnings Call Transcript

Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China's National Medical Products Administration (“NMPA”) has granted Breakthrough Therapy Designation (“BTD”) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer (“EMC”) with pMMR1 tumors that have failed at least one line of platinum-based therapy. A study for potential registration of this combination in patients with previously treated advanced EMC in China has recently completed enrollment.

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

The mean of analysts' price targets for HUTCHMED (HCM) points to a 141.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think HUTCHMED (HCM) Could Surge 141.13%: Read This Before Placing a Bet

Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee

HUTCHMED Announces Changes to Board of Directors and Technical Committee

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a Phase I study in China of HMPL-415, an investigational novel selective allosteric inhibitor targeting Src homology-2 domain-containing protein tyrosine phosphatase-2 (“SHP2”). The first patient received their first dose on July 6, 2023.

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2023 on Monday, July 31, 2023 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).

HUTCHMED to Announce 2023 Half-Year Financial Results

— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) —

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data related to two novel investigational hematological malignancy therapies, HMPL-306 and amdizalisib, will be presented at the upcoming European Hematology Association (“EHA”) Annual Meeting, taking place June 8-11, 2023 in Frankfurt, and the 17th International Conference on Malignant Lymphoma (“ICML”) taking place June 13-17, 2023 in Lugano.

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO-2 and FRESCO clinical trials — OSAKA, Japan and CAMBRIDGE, Mass. and HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J.

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated clinical data related to HUTCHMED's novel investigational cancer therapies fruquintinib, surufatinib and HMPL-453 in 21 abstracts that will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL and online.

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) refers to its announcement on May 10, 2023 of the appointment of Professor Solange Peters as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company with effect from the conclusion of the annual general meeting of the Company to be held on May 12, 2023 (“AGM”). The Company today announces that the effective date of such appointments will be deferred until a later date to be announced by the Company.

HUTCHMED Announces Board of Directors and Board Committee Membership

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Solange Peters is appointed as an Independent Non-executive Director, member of the Technical Committee and member of the Audit Committee of the Company with effect from the conclusion of the annual general meeting of the Company to be held on May 12, 2023. Professor Peters is a renowned scientist and educator who possesses expertise and extensive experience in oncology and immunology. The Board of HUTCHMED is of the view that Professor Peters will make significant contributions to the Company.

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees

The consensus price target hints at a 103.8% upside potential for HUTCHMED (HCM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 103.84% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. , April 17, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that its New Drug Application (“NDA”) for fruquintinib in combination with paclitaxel for the treatment of second-line advanced gastric or gastroesophageal junction adenocarcinoma in China has been accepted for review by the China National Medical Products Administration (“NMPA”).

News for Hutchison China MediTech Ltd. Stock (HCM)